Tibet Weixinkang Medicine
Launch date
Employees
Market cap
€408m
Enterprise valuation
€278m (Public information from Sep 2024)
Share price
CNY7.51 603676.SS
Lhasa Tibet (HQ)
Financials
Estimates*
| CNY | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | - | 741m | 716m | 1.0b | 1.4b | 1.3b | 16.5b |
| % growth | - | - | (3 %) | 44 % | 35 % | (5 %) | - |
| EBITDA | - | 74.8m | 75.8m | 155m | 247m | 252m | - |
| % EBITDA margin | - | 10 % | 11 % | 15 % | 18 % | 19 % | - |
| Profit | - | 55.7m | 58.4m | 95.9m | 177m | 214m | - |
| % profit margin | - | 8 % | 8 % | 9 % | 13 % | 16 % | - |
| EV / revenue | - | 5.3x | 4.5x | 3.2x | 4.4x | 2.8x | - |
| EV / EBITDA | - | 52.9x | 42.6x | 21.6x | 24.8x | 14.5x | - |
| R&D budget | - | 29.1m | 23.2m | 38.0m | 72.5m | 113m | - |
| R&D % of revenue | - | 4 % | 3 % | 4 % | 5 % | 9 % | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
| Total Funding | - | ||
